| Schedule of Reconciliation Including Such Costs to Our Consolidated Net Loss |
Based on certain significant period cost information regularly provided to our Chief Operating Decision Maker, following is a reconciliation of such costs to our consolidated net income (loss) for the three and six months ended June 30, 2026 and 2025:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended June 30, |
|
|
Six months ended June 30, |
|
($ in thousands) |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
Product |
|
$ |
22,405 |
|
|
$ |
15,867 |
|
|
$ |
34,167 |
|
|
$ |
34,069 |
|
Service |
|
|
3,752 |
|
|
|
4,126 |
|
|
|
9,255 |
|
|
|
6,727 |
|
Total revenue |
|
|
26,157 |
|
|
|
19,993 |
|
|
|
43,422 |
|
|
|
40,796 |
|
Cost of revenue |
|
|
|
|
|
|
|
|
|
|
|
|
Product |
|
|
24,605 |
|
|
|
18,876 |
|
|
|
38,413 |
|
|
|
38,987 |
|
Service |
|
|
3,786 |
|
|
|
5,036 |
|
|
|
8,470 |
|
|
|
9,175 |
|
Total cost of revenue |
|
|
28,391 |
|
|
|
23,912 |
|
|
|
46,883 |
|
|
|
48,162 |
|
Gross loss |
|
|
(2,234 |
) |
|
|
(3,919 |
) |
|
|
(3,461 |
) |
|
|
(7,366 |
) |
Less: significant segment period costs: |
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation expense |
|
|
(1,519 |
) |
|
|
(688 |
) |
|
|
(4,211 |
) |
|
|
(725 |
) |
Personnel costs (excluding stock-based compensation) |
|
|
(5,409 |
) |
|
|
(3,516 |
) |
|
|
(9,137 |
) |
|
|
(7,826 |
) |
Credit loss credits (provisions) |
|
|
40 |
|
|
|
(284 |
) |
|
|
38 |
|
|
|
(192 |
) |
Other segment expenses(1) |
|
|
(4,605 |
) |
|
|
(3,092 |
) |
|
|
(9,014 |
) |
|
|
(5,950 |
) |
Interest expense |
|
|
(4,333 |
) |
|
|
(731 |
) |
|
|
(8,229 |
) |
|
|
(1,442 |
) |
Interest income |
|
|
5 |
|
|
|
5 |
|
|
|
10 |
|
|
|
11 |
|
Gain from disposal of investment in unconsolidated subsidiary |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
3,204 |
|
Gain on sale of Atlas |
|
|
26 |
|
|
|
50 |
|
|
|
26 |
|
|
|
50 |
|
Gain (loss) from change in fair value of warrant liability |
|
|
(8,887 |
) |
|
|
(2,836 |
) |
|
|
39,855 |
|
|
|
1,768 |
|
Other income, net |
|
|
9 |
|
|
|
71 |
|
|
|
10 |
|
|
|
75 |
|
Loss from unconsolidated subsidiary |
|
|
— |
|
|
|
(451 |
) |
|
|
— |
|
|
|
(563 |
) |
Provision for income taxes |
|
|
(217 |
) |
|
|
(39 |
) |
|
|
(412 |
) |
|
|
(293 |
) |
Net income (loss) |
|
$ |
(27,124 |
) |
|
$ |
(15,430 |
) |
|
$ |
5,475 |
|
|
$ |
(19,249 |
) |
Supplemental information: |
|
|
|
|
|
|
|
|
|
|
|
|
Indirect personnel costs (excluding stock-based compensation) in cost of revenue |
|
$ |
2,515 |
|
|
$ |
2,455 |
|
|
$ |
5,161 |
|
|
$ |
4,958 |
|
Total depreciation and amortization expense |
|
$ |
430 |
|
|
$ |
305 |
|
|
$ |
795 |
|
|
$ |
607 |
|
Capital expenditures |
|
$ |
319 |
|
|
$ |
185 |
|
|
$ |
595 |
|
|
$ |
268 |
|
Total assets at period end |
|
$ |
98,059 |
|
|
$ |
82,955 |
|
|
$ |
98,059 |
|
|
$ |
82,955 |
|
|
|
(1) |
Other segment expenses include research and development material and lab expenditures, professional services, marketing, employee travel, facility, insurance, depreciation and amortization and certain other period costs. |
|